How It Works
Using a unique combination of helium plasma and radiofrequency (RF) energy, Renuvion quickly heats to the ideal temperature for tissue contraction, allowing you to achieve the best possible results in a short period of time.1,2,3,4,5,6 This minimally invasive procedure can be performed with a local anesthetic or while the patient is asleep.6
During the procedure the Renuvion energy is applied to the subdermal space. This heating is done quickly and the tissue is cooled back to baseline in less than 1 second.1,2,3,4,5,7
The use of Renuvion does not require skin excision, and therefore is considered a minimally invasive procedure. The device is inserted subdermally through small entry points, which reduces post-operative discomfort and scarring.7
The procedure is minimally invasive with no surgical removal of tissue. With the use of small entry points and minimal disruption of the tissue, patients experience less pain, discomfort, and downtime with Renuvion compared to more invasive procedures.8
With Renuvion we know it is possible to contract soft tissues and start the collagen rebuilding process known as neocollagensis. This process takes 6-9 months which is why effects will improve over time.1,2,3,4,5,7
The Renuvion system is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open surgical procedures. The Apyx® Plasma/RF Handpiece (APR HP) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue.
The Renuvion system has received a general clearance and has not been determined to be safe or effective for use in any specific indication or anatomical location. Apyx Medical does not promote its general clearance products for any specific surgical specialty or subspecialty.
Risk associated with the use of the Renuvion system for subdermal coagulation may include: Helium embolism into the surgical site due to inadvertent introduction into the venous or arterial blood supply system, unintended burns (deep or superficial), pneumothorax, temporary or permanent nerve injury, ischemia, fibrosis, infection, pain, discomfort, gas buildup resulting in temporary and transient crepitus or pain, bleeding, hematoma, seroma, subcutaneous induration, pigmentation changes, increased healing time, unsatisfactory scarring, asymmetry and/or unacceptable cosmetic result. There may be additional risks associated with the use of other devices along with Renuvion and there may be an increased risk for patients who have undergone prior surgical or aesthetic procedures in the treatment area. As with any procedure, individual results may vary. As with all energy devices there are inherent risks associated with its use, refer to the IFU for further information.
- Feldman LS, et al. (eds). The SAGES Manual on the Fundamental Use of Surgical Energy (FUSE), ISBN 978‐1‐4614‐2073‐6.
- Chen SS, Wright NT, Humphrey JD. Heat-induced changes in the mechanics of a collagenous tissue: isothermal free shrinkage. Journal of Biomechanical Engineering 1997:109:372-378.
- McDonald MB. Conductive Keratoplasty: A Radiofrequency-based Technique for the Correction of Hyperopia. Trans Am Ophthalmol Soc 2005;103:512-536.
- Chen SS, Humphrey JD. Heat-induced changes in the mechanics of a collagenous tissue: pseudoelastic behavior at 37° C. J Biomech 1998;31:211-216.
- Wright NT, Humphrey JD. Denaturation of collagen during heating: An irreversible rate process. Annu Rev Biomed Eng; 2002;4:109-128.
- Duncan DI and Roman S. Helium Plasma Subdermal Tissue Contraction Method of Action. Biomed J Sci & Tech Res 31(2)-2020. BJSTR. MS.ID.005075.
- Renuvion Physician Survey Results, MM0317.01 0422 – https://www.renuvion.com/wp-content/uploads/2022/05/renuvion-physician-survey-results-brochure_mm0317.01_050222.pdf.
- Mohiuddin K, Swanson SJ. Maximizing the benefit of minimally invasive surgery. J Surg Oncol. 2013 Oct;108(5):315-9. doi: 10.1002/jso.23398. Epub 2013 Aug 23. PMID: 24037974.